Cannabis Law and Access in Argentina

Argentina's cannabis law is more complicated than the headlines suggest

Forty-seven countries had some form of cannabis regulatory framework by the end of 2023, according to the UNODC's most recent global drug policy survey. Argentina sits among them , but its model doesn't map neatly onto either the "fully legal" or "strictly prohibited" boxes that most international summaries default to. I've spent some time working through the Spanish-language legislation alongside the English summaries, and the short version is: Argentina has built a genuinely tiered system, and the tiers matter quite a bit depending on who you are and what you're trying to do.

For Australian readers, a firm note upfront: none of what follows reflects Australian law. If you're in Australia, cannabis access is governed by the TGA's Special Access Scheme, the Authorised Prescriber pathway, and the scheduling provisions of the Poisons Standard. What Argentina does is Argentina's business. This article is descriptive, comparative, and , I'd argue , genuinely interesting from a regulatory design perspective.

The foundation: Law 27,350 and its evolution

Argentina's cannabis regulatory story really starts with Law 27,350, passed in March 2017. The law was driven largely by families of children with refractory epilepsy and by civil society organisations that had been cultivating cannabis for their own use; sometimes quite publicly, before any formal framework existed.

Law 27,350 established a national programme for research and medical use of cannabis and its derivatives. Critically, it authorised the use of cannabidiol (CBD) for medicinal purposes under medical supervision, though the original text was narrow and implementation was slow. It also created a framework for CONICET (the national science and technology research council) and public universities to conduct cannabis research.

A significant expansion came with Decree 883/2020, which broadened the programme considerably. This decree authorised home cultivation for personal medicinal use and for registered patient associations, and it extended the regulatory scope to include products containing THC, not just CBD. ANMAT, Argentina's medicines and food safety regulator (roughly analogous to the TGA), was tasked with oversight of industrial and pharmaceutical cannabis production.

Cultivation: home grows, patient associations, and industrial licences

This is where Argentina's framework genuinely diverges from most comparable countries. The 2020 decree created three distinct cultivation tracks.

First, registered individual patients and their designated carers may cultivate cannabis plants at home for personal medicinal use. Registration is administered through the national health ministry's cannabis programme (REPROCANN). Second, patient associations and civil society organisations; some of which had been operating informally for years before 2020, can register as collective cultivators to supply their members. Third, licences exist for private companies to cultivate at industrial scale for pharmaceutical manufacturing, with ANMAT oversight.

The REPROCANN register had reportedly processed over 100,000 registrations by 2023, according to reporting by Argentina's official national health secretariat. That's a notable uptake for a registration-based system.

Personal recreational use of small quantities occupies its own legal space entirely. A 2009 Supreme Court ruling, the "Arriola" decision; found that prosecuting personal possession and use of small amounts for private use was unconstitutional under Argentina's right to privacy provisions. This doesn't legalise recreational use; it creates a practical barrier to prosecution. Argentina has not passed legislation fully legalising recreational cannabis at the federal level. Several proposals have been debated in the legislature, but as of mid-2025, recreational legalisation has not been enacted federally.

What the products look like: cannabinoids and formulations

Pharmaceutically, registered cannabis products in Argentina must meet ANMAT's manufacturing and quality standards. The regulatory framework covers both CBD-dominant products and those containing THC. From a chemistry standpoint, the cannabinoids most relevant to the pharmaceutical framework are CBD and THC, the two most studied and most commonly incorporated into formulations. Other minor cannabinoids like CBG and CBD variants appear in research contexts, though they're less prominent in the approved product landscape.

The endocannabinoid system is the biological framework through which these compounds act. Both CB1 receptors and CB2 receptors are involved, CB1 receptors are found primarily in the central nervous system, CB2 receptors more broadly in peripheral tissue. This is basic pharmacology, not a claim about what any product does clinically. I raise it because the regulatory debate in Argentina, as in Australia, has always tracked the science: as mechanistic understanding developed, access frameworks followed. It's worth understanding the biology if you're going to make sense of the policy.

Home cultivators who are registered under REPROCANN are not producing pharmaceutically standardised products, obviously. What they produce varies considerably. For readers interested in what "standardised" means in a product context, our glossary entry on standardised extract is a reasonable starting point.

Export and industrial ambitions

Argentina has moved to position itself as a cannabis export economy, particularly for pharmaceutical-grade products. Law 27,669, passed in 2022, specifically addressed industrial hemp and medical cannabis cultivation for export, loosening some of the restrictions on licensed producers.

I'll admit my mild scepticism here: frameworks for cannabis export often look better on paper than they perform in practice, particularly where bilateral treaty obligations and import-country regulations create friction. Several Latin American countries have passed similar export-oriented legislation and found the international pharmaceutical market slower to open than expected. Argentina's export ambitions are genuine, but the regulatory pathway from licensed grower to overseas pharmaceutical customer is long and involves more than one jurisdiction's approval processes.

How Argentina compares; and why Australians should read this critically

I spent part of last Saturday on a long road ride out toward the Canberra-Queanbeyan fringe, listening to a podcast about comparative drug policy in the Americas, which is either the nerdiest thing I've done this month or exactly on-brand. The point one academic made stuck with me: Argentina's framework is unusual because it developed largely in response to civil society pressure from patient groups, rather than top-down legislative design. That's a different political economy from Australia's, where the TGA-centred model is fundamentally regulatory-agency-driven.

Australia's access pathways, the Special Access Scheme and Authorised Prescriber system, require a prescriber's involvement for access to scheduled cannabis medicines. Medicinal cannabis products registered on the ARTG sit as either Schedule 4 or Schedule 8 medicines under the Poisons Standard. Home cultivation of cannabis remains illegal under Australian law regardless of any overseas comparison. These are not analogous frameworks and should not be treated as interchangeable.

Argentina's model is interesting to study precisely because it took a different path. Whether that path produces better patient outcomes or greater regulatory coherence is a question researchers are still working through, and the honest answer is that the evidence base is early.

The limits of the framework in practice

Registration under REPROCANN has been uneven in practice. Access in rural provinces has lagged behind Buenos Aires. The quality and potency of home-cultivated cannabis products is uncontrolled by any standard the way pharmaceutical-grade materials would be; which raises real questions about consistency for patients who need reliable dosing. ANMAT-approved pharmaceutical products address this, but availability and affordability remain access barriers for many Argentinians.

Provincially, enforcement of the Arriola precedent has been inconsistent. Some provinces have seen ongoing police action despite the constitutional protection, particularly against cultivators who aren't registered under the national programme. The law on paper and the law in practice don't always match, and this gap is documented in reporting by Argentina's civil society cannabis organisations.

None of this is unique to Argentina, of course. It's a pattern familiar to anyone who reads comparative drug policy carefully. Frameworks that look coherent at the federal level often fragment at the implementation stage. Worth keeping that in mind when evaluating any country's cannabis model, including our own.

Sources

• Ley 27.350, Programa Nacional para el Estudio y la Investigación del Uso Medicinal de la Planta de Cannabis; Gobierno de Argentina
• Cannabis Legislation Overview, United Nations Office on Drugs and Crime (UNODC)
• Medicinal Cannabis Guidance Documents, Therapeutic Goods Administration (TGA)
• WHO Expert Committee on Drug Dependence: Cannabis and Cannabis-Related Substances; World Health Organization

, Marcus Hale, Regulatory researcher, TGA & access law